Menu

MD Anderson Cancer Center Head Resigns

Ronald DePinho tells institute employees it is “time for a change in leadership.”

Mar 9, 2017
Tracy Vence

The University of Texas MD Anderson Cancer Center president is stepping down. Ronald DePinho, who has led the institution for nearly six years and was involved in managerial and financial controversies, wrote in a letter to his staff that it is “time for a change in leadership.”

As the Houston Chronicle noted, “DePinho’s [leadership] at MD Anderson was marked by change, criticism, and challenges.” In March 2013, for example, around one-third of institute employees who responded to a survey indicated dissatisfaction with his management. That May, The Cancer Letter reported that the institute spent around $1.5 million in building renovations for DePinho’s wife, Lydia Chin, chair of MD Anderson’s genomic medicine department. The institute disputed the report at the time.

In 2016, the institute reported significant operating losses. MD Anderson “was expecting to lose as much as $450 million in 2017,” STAT News reported, “though it brings in about $4 billion in annual revenue.”

“In an era of significant and rapid financial change, we are recovering well from short-term challenges and, longer term, have diversified our revenue streams through philanthropy, strategic ventures and innovation,” DePinho wrote in his letter, adding: “I could have done a better job administratively, a better job listening, a better job communicating. Forgive me for my short comings [sic].”

THUMBNAIL IMAGE: WIKIMEDIA, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.